StreetInsider.com News Articles

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program

CAMBRIDGE, Mass., July 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced it intends to proceed with the filing of a New Drug Submission (NDS) to Health Canada (the "Agency") for PrimeC for the treatment of amyotrophic

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Wed, 22 Jul 2026 08:30:00 -0400

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

CAMBRIDGE, Mass., July 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced its participation in a key opinion leader (KOL) webinar hosted by Roth Capital Partners titled "A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)." The webinar will bring together leading experts to discuss the current treatment landscape

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward